PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1

BACKGROUND: Mutant isocitrate dehydrogenase (mIDH) enzymes produce the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (IVO; AG-120) is a first-in-class oral inhibitor of mIDH1 being evaluated in 66 glioma patients (pts) in an ongoing phase 1 study (NCT02073994). Vorasidenib (VOR; AG-881) is...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Mellinghoff, I K, Wen, P Y, Taylor, J W, Maher, E A, Arrillaga-Romany, I, Peters, K B, Le, K, Tai, F, Steelman, L, Cloughesy, T F
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Oral Presentations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6794942/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.004
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki